SE461854B - Acetylerytromycinstearat och terapeutisk komposition innehaallande det - Google Patents
Acetylerytromycinstearat och terapeutisk komposition innehaallande detInfo
- Publication number
- SE461854B SE461854B SE8406671A SE8406671A SE461854B SE 461854 B SE461854 B SE 461854B SE 8406671 A SE8406671 A SE 8406671A SE 8406671 A SE8406671 A SE 8406671A SE 461854 B SE461854 B SE 461854B
- Authority
- SE
- Sweden
- Prior art keywords
- stearate
- erythromycin
- acetylerythromycin
- tablets
- ethyl acetate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 8
- 230000001225 therapeutic effect Effects 0.000 title 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 241000428352 Amma Species 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 235000021552 granulated sugar Nutrition 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 25
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 13
- 229960004142 erythromycin stearate Drugs 0.000 description 12
- 229960003276 erythromycin Drugs 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- -1 acetate ester Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960003203 erythromycin estolate Drugs 0.000 description 2
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RJUFATJOENABQE-UHFFFAOYSA-N (2,2,2-trichloro-1-diphenoxyphosphorylethyl) acetate Chemical compound C=1C=CC=CC=1OP(=O)(C(C(Cl)(Cl)Cl)OC(=O)C)OC1=CC=CC=C1 RJUFATJOENABQE-UHFFFAOYSA-N 0.000 description 1
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001530392 Aphos Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004213 erythromycin lactobionate Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK5884A DK149776C (da) | 1984-01-06 | 1984-01-06 | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8406671D0 SE8406671D0 (sv) | 1984-12-28 |
| SE8406671L SE8406671L (sv) | 1985-07-07 |
| SE461854B true SE461854B (sv) | 1990-04-02 |
Family
ID=8089251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8406671A SE461854B (sv) | 1984-01-06 | 1984-12-28 | Acetylerytromycinstearat och terapeutisk komposition innehaallande det |
Country Status (38)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874614A (en) * | 1985-03-25 | 1989-10-17 | Abbott Laboratories | Pharmaceutical tableting method |
| US4863741A (en) * | 1985-03-25 | 1989-09-05 | Abbott Laboratories | Tablet composition for drug combinations |
| JP3382159B2 (ja) * | 1998-08-05 | 2003-03-04 | 株式会社東芝 | 情報記録媒体とその再生方法及び記録方法 |
| US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| US7399488B2 (en) * | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| CA2543945A1 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid |
| EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
| EP2457580A1 (en) | 2004-08-25 | 2012-05-30 | The UAB Research Foundation | Absorption enhancers for drug administration |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| CA2714867A1 (en) | 2006-06-23 | 2007-12-27 | Candace B. Pert | Non-aggregated pharmaceutically active peptide |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| KR102512178B1 (ko) | 2011-05-18 | 2023-03-20 | 메더리스 다이어비티즈, 엘엘씨 | 개선된 펩티드 제약 |
| AU2013347975B2 (en) | 2012-11-20 | 2018-07-26 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| CA2891929C (en) | 2012-11-20 | 2022-07-19 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| WO2014140699A1 (en) * | 2013-03-13 | 2014-09-18 | Calyx Chemicals And Pharmaceuticals Ltd | A novel process of liberation of erythromycin and preparation of its salts |
| EP4397374A3 (en) | 2014-05-28 | 2024-10-16 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for insulin resistance |
| WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
| RU2019142102A (ru) | 2017-05-19 | 2021-06-21 | Лунелла Байотек, Инк. | Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток |
| US11497759B2 (en) | 2017-12-01 | 2022-11-15 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| EP4483958A3 (en) | 2018-02-06 | 2025-03-05 | Aegis Therapeutics, LLC | Intranasal epinephrine formulations and methods for the treatment of disease |
| JP6941224B2 (ja) | 2018-02-06 | 2021-09-29 | イージス セラピューティクス，エルエルシー | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 |
| KR20210104830A (ko) * | 2018-12-17 | 2021-08-25 | 루넬라 바이오테크 인코포레이티드 | 항노화를 위한 삼중 조합 요법 |
| BR112021011963A2 (pt) * | 2018-12-17 | 2021-09-08 | Lunella Biotech, Inc. | Terapias de combinação tripla para alvejamento de mitocôndria e exterminação de células-tronco de câncer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1011117B (de) * | 1953-11-16 | 1957-06-27 | Abbott Lab | Verfahren zur Herstellung von reinen stabilen Erythromycin-Saeure-Additionssalzen |
| FR1179208A (fr) * | 1953-11-16 | 1959-05-21 | Abbott Lab | Procédé de préparation de sels d'érythromycine |
| GB834397A (en) * | 1958-07-29 | 1960-05-04 | Lilly Co Eli | Therapeutic compositions comprising erythromycin esters |
| US4150220A (en) * | 1977-02-04 | 1979-04-17 | Pfizer Inc. | Semi-synthetic 4"-erythromycin A derivatives |
| FR2473525A1 (fr) * | 1980-01-11 | 1981-07-17 | Roussel Uclaf | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
-
1984
- 1984-01-06 DK DK5884A patent/DK149776C/da not_active IP Right Cessation
- 1984-12-18 NZ NZ210606A patent/NZ210606A/en unknown
- 1984-12-20 IL IL73885A patent/IL73885A/xx not_active IP Right Cessation
- 1984-12-21 GB GB08432368A patent/GB2152502B/en not_active Expired
- 1984-12-21 AU AU37059/84A patent/AU565688B2/en not_active Ceased
- 1984-12-27 US US06/686,753 patent/US4599326A/en not_active Expired - Fee Related
- 1984-12-28 BE BE0/214265A patent/BE901411A/fr not_active IP Right Cessation
- 1984-12-28 ZA ZA8410143A patent/ZA8410143B/xx unknown
- 1984-12-28 SE SE8406671A patent/SE461854B/sv not_active IP Right Cessation
- 1984-12-28 IS IS2968A patent/IS2968A7/is unknown
- 1984-12-28 PT PT79777A patent/PT79777B/pt not_active IP Right Cessation
- 1984-12-31 NL NL8403979A patent/NL8403979A/nl not_active Application Discontinuation
-
1985
- 1985-01-02 NO NO850007A patent/NO160263C/no unknown
- 1985-01-02 FR FR8500005A patent/FR2557878B1/fr not_active Expired
- 1985-01-02 MA MA20540A patent/MA20316A1/fr unknown
- 1985-01-03 FI FI850023A patent/FI77249C/fi not_active IP Right Cessation
- 1985-01-03 AT AT0000985A patent/AT386414B/de not_active IP Right Cessation
- 1985-01-04 HU HU8537A patent/HU196221B/hu not_active IP Right Cessation
- 1985-01-04 IT IT19012/85A patent/IT1184304B/it active
- 1985-01-04 CS CS8596A patent/CS247191B2/cs unknown
- 1985-01-04 CA CA000471563A patent/CA1224461A/en not_active Expired
- 1985-01-04 CH CH31/85A patent/CH666275A5/de not_active IP Right Cessation
- 1985-01-04 PL PL1985251457A patent/PL144349B1/pl unknown
- 1985-01-04 LU LU85721A patent/LU85721A1/fr unknown
- 1985-01-04 DE DE19853500179 patent/DE3500179A1/de active Granted
- 1985-01-04 SU SU853836820A patent/SU1410866A3/ru active
- 1985-01-04 KR KR1019850000008A patent/KR900006237B1/ko not_active Expired
- 1985-01-04 IE IE22/85A patent/IE57967B1/en not_active IP Right Cessation
- 1985-01-04 ES ES539349A patent/ES8605818A1/es not_active Expired
- 1985-01-04 YU YU20/85A patent/YU44485B/xx unknown
- 1985-01-05 BG BG068285A patent/BG43189A3/xx unknown
- 1985-01-07 RO RO117230A patent/RO91262B/ro unknown
- 1985-01-07 JP JP60000744A patent/JPS60158197A/ja active Granted
- 1985-01-07 PH PH31689A patent/PH22471A/en unknown
- 1985-01-07 MX MX203973A patent/MX156277A/es unknown
-
1988
- 1988-10-28 KE KE3841A patent/KE3841A/xx unknown
-
1989
- 1989-07-21 CY CY1462A patent/CY1462A/en unknown
-
1990
- 1990-02-15 HK HK115/90A patent/HK11590A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE461854B (sv) | Acetylerytromycinstearat och terapeutisk komposition innehaallande det | |
| JPH0784424B2 (ja) | チロシン誘導体及びその用途 | |
| JPH0283326A (ja) | 原虫感染症治療用組成物 | |
| EA021683B1 (ru) | Производные деоксиактагардина в | |
| JPS608000B2 (ja) | アミノフエニル誘導体及び該誘導体を含有する生理活性剤 | |
| RU2454230C2 (ru) | Лечение и профилактика заболеваний и инфекций свиней и домашней птицы | |
| CN111233831A (zh) | 常山铜琥珀酸单酯及其制备方法与用途 | |
| JPH0778021B2 (ja) | 下痢症ウイルス感染阻害剤 | |
| JPH0645543B2 (ja) | 魚病の予防，治療剤 | |
| GB1577545A (en) | Treatment of swine dysenter | |
| US4686207A (en) | Erythromycin A 11,12-carbonates and method of use | |
| CN101879177B (zh) | 爱乐新用于制备治疗由鼻腔鸟杆菌引起的疾病的药剂的用途 | |
| CN1159756A (zh) | 抑制白细胞介素5的产生的抑制剂 | |
| KR850000966B1 (ko) | Dmt의 c-23-변형 유도체의 제조방법 | |
| JPH0586374B2 (enExample) | ||
| US3013942A (en) | Therapeutic erythromycin ester compositions | |
| JPS60218321A (ja) | 消化管収縮運動促進剤 | |
| JPH07179348A (ja) | スクロースアシル体を有効成分とする脳機能改善剤 | |
| JPS6234038B2 (enExample) | ||
| JP3406334B2 (ja) | チロシン特異的リン酸化酵素阻害剤及び制癌剤 | |
| JPS5950318B2 (ja) | 新規抗生物質ｓｙ−２物質 | |
| JPS63218679A (ja) | カチオノマイシン誘導体及び抗コクシジウム剤 | |
| JPS59161386A (ja) | セフアロスポリン誘導体及び該誘導体を含有する医薬 | |
| JPH07179487A (ja) | 新規キサントン配糖体およびその用途 | |
| JPS5939409B2 (ja) | オルト又はメタアミノ安息香酸誘導体を含有する抗腫瘍剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8406671-1 Effective date: 19940710 Format of ref document f/p: F |